Updated view of tars for psoriasis: what have we learned over the last decade?
coal tar
pine tar
psoriasis
safety
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
revised:
15
02
2022
received:
17
01
2022
accepted:
20
03
2022
pubmed:
11
4
2022
medline:
25
2
2023
entrez:
10
4
2022
Statut:
ppublish
Résumé
Tars are one of the most effective, unknown, and oldest therapies for psoriasis. They include coal tar (CT) and biomass-derived products. These treatments, particularly the CT, have proven to be cost-effective with long remission times compared to other systemic or topical treatments. However, they have hardly evolved in recent years, as they are not well-embraced by clinicians or patients because of concerns regarding cosmesis and safety. This review summarizes current knowledge about the chemical characterization, mechanism of action, toxicity, and clinical studies supporting the use of tars for psoriasis over the last decade. Trends within these above aspects are reviewed, and avenues of research are identified. CT is rich in polycyclic aromatic hydrocarbons, whereas biomass-derived tars are rich in phenols. While the activation of the aryl hydrocarbon receptor is involved in the antipsoriatic effect of CT, the mechanism of action of biomass-derived products remains to be elucidated. No conclusive evidence exists about the risk of cancer in psoriasis patients under CT treatment. Large, randomized, double-blind, controlled clinical trials are necessary to promote the inclusion of tars as part of modern therapies for psoriasis.
Substances chimiques
Tars
0
Coal Tar
8007-45-2
Dermatologic Agents
0
Cosmetics
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
290-301Subventions
Organisme : Consejo Nacional de Ciencia y Tecnología
ID : 759324
Informations de copyright
© 2022 the International Society of Dermatology.
Références
Zhu TH, Nakamura M, Farahnik B, et al. The patient's guide to psoriasis treatment. Part 4: Goeckerman therapy. Dermatol Ther (Heidelb) 2016; 6: 333-339.
USP29-NF24. USP monographs: coal tar topical solution [Internet]. U.S. Pharmacopeia. [citado 23 de marzo de 2021]. Disponible en: http://www.pharmacopeia.cn/v29240/usp29nf24s0_m19140.html
Barnes TM, Greive KA. Topical pine tar: History, properties and use as a treatment for common skin conditions. Australas J Dermatol 2017; 58: 80-85.
Esquivel-García R, Ayiania M, Abu-Lail N, et al. Pyrolytic oils from Amphipterygium adstringens bark inhibit IL-8 production of IL-17-stimulated HaCaT keratinocytes. J Anal Appl Pyrol 2020; 145: 104749.
Sun M, Zhang D, Yao Q, et al. Separation and composition analysis of GC/MS analyzable and unanalyzable parts from coal tar. Energy Fuel 2018; 32: 7404-7411.
Sekhon S, Jeon C, Nakamura M, et al. Review of the mechanism of action of coal tar in psoriasis. J Dermatol Treat 2018; 29: 230-232.
Jones SK, Mackie RM, Hole DJ, et al. Further evidence of the safety of tar in the management of psoriasis. Br J Dermatol 1985; 113: 97-101.
Allen LV. Basics of compounding with tars. Int J Pharm Compd 2013; 17: 400-410.
Ku CS, Mun SP. Characterization of pyrolysis tar derived from lignocellulosic biomass. J Ind Eng Chem 2006; 12: 853-861.
Schröder-Kraft C. Other topical therapies (dyes, tanning agents, tars, CO2). In: John SM, Johansen JD, Rustemeyer T, Elsner P, Maibach HI, editores. Kanerva's occupational dermatology. Cham: Springer International Publishing; 2020 [citado 23 de marzo de 2021]. p. 1475-82. Disponible en: https://doi.org/10.1007/978-3-319-68617-2_96
Calautti E, Avalle L, Poli V. Psoriasis: A STAT3-centric view. Int J Mol Sci 2018; 19: 171.
van den Bogaard EH, Bergboer JGM, Vonk-Bergers M, et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest 2013; 123: 917.
Beránek M, Fiala Z, Kremláček J, et al. Serum levels of aryl hydrocarbon receptor, cytochromes P450 1A1 and 1B1 in patients with exacerbated psoriasis vulgaris. Folia Biol (Praha) 2018; 64: 97-102.
Di Meglio P, Duarte JH, Ahlfors H, et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity 2014; 40: 989-1001.
Smits JPH, Ederveen THA, Rikken G, et al. Targeting the cutaneous microbiota in atopic dermatitis by coal tar via AHR-dependent induction of antimicrobial peptides. J Invest Dermatol 2020; 140: 415-424.e10.
Szelest M, Walczak K, Plech T. A new insight into the potential role of tryptophan-derived AhR ligands in skin physiological and pathological processes. Int J Mol Sci 2021; 22: 1104.
Zhu Z, Chen J, Lin Y, et al. Aryl hydrocarbon receptor in cutaneous vascular endothelial cells restricts psoriasis development by negatively regulating neutrophil recruitment. J Invest Dermatol 2020; 140: 1233-1243.e9.
Hon KL, Ng WGG, Kung JSC, et al. Pilot studies on two complementary bath products for atopic dermatitis children: Pine-tar and tea. Medicines 2019; 6: 8.
Ng WGG, Hon KL, Kung JSC, et al. Effect of pine-tar bath on disease severity in moderate-to-severe childhood eczema: An investigator-blinded, crossover, randomized clinical trial. J Dermatol Treat 2020; 0: 1-9.
Alqahtani EA, Elagib MFA, Al-Yami RH, et al. Evaluation of antibacterial activity of pine tar on periodontal pathogenic bacteria: An in vitro study. Ethiop J Health Sci 2020; 30: 991-998.
Brownstone ND, Bridges A, Bhutani T, et al. Seeing the treatment of psoriasis in a new light: a novel medical device utilizing localized coal tar and narrowband UVB for targeted treatment of plaque psoriasis. J Drugs Dermatol 2021; 20: 701-702.
El-Darouti MA, Gawdat HI, Hegazy RA, et al. Crude coal tar and ultraviolet (UV) a radiation (modified Goeckerman technique) in treatment of psoriasis. Acta Dermatovenerol Croat 2015; 23: 165-170.
Rajappa M, Rathika S, Munisamy M, et al. Effect of treatment with methotrexate and coal tar on adipokine levels and indices of insulin resistance and sensitivity in patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2015; 29: 69-76.
Khandpur S, Sahni K. An open label prospective randomized trial to compare the efficacy of coal tar-salicylic acid ointment versus calcipotriol/betamethasone dipropionate ointment in the treatment of limited chronic plaque psoriasis. Indian J Dermatol 2014; 59: 579-583.
Singh P, Gupta S, Abidi A, et al. Comparative evaluation of topical calcipotriol versus coal tar and salicylic acid ointment in chronic plaque psoriasis. J Drugs Dermatol 2013; 12: 868-873.
Khandpur S, Sharma VK. Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet a therapy in palmoplantar psoriasis. Clin Exp Dermatol 2011; 36: 613-616.
Alora-Palli MB, Perkins AC, van Cott A, et al. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis. Am J Clin Dermatol 2010; 11: 275-283.
Kumar U, Kaur I, Dogra S, et al. Topical tazarotene vs. coal tar in stable plaque psoriasis. Clin Exp Dermatol 2010; 35: 482-486.
Zhang J, Jiang GP, Fan P. Observation on therapeutic effect of mineral spring baths combined with 5% pine tar ointments in the treatment of psoriasis vulgaris. Chin Med J 2010; 24: 140-141.
Zhang Y-H, Guo Z-P, Jiao X-Y, et al. Clinical observation of TGP in the treatment of psoriasis vulgaris. J Clin Dermatol 2011; 40: 433-435.
Moustafa G-A, Xanthopoulou E, Riza E, et al. Skin disease after occupational dermal exposure to coal tar: a review of the scientific literature. Int J Dermatol 2015; 54: 868-879.
Penning TM. Human Aldo-keto reductases and the metabolic activation of polycyclic aromatic hydrocarbons. Chem Res Toxicol 2014; 27: 1901-1917.
Hessel AB, Fabbro SK, Marshall D, Cruz Ramón JC. Agents used for treatment of hyperkeratosis. In: Wolverton SE, Wu JJ, editores. Comprehensive dermatologic drug therapy. 4th ed. Elsevier; 2021. p. 607-616.e4. Disponible en. [citado 24 de febrero de 2021]: https://doi.org/10.1016/B978-0-323-61211-1.00055-3
Roelofzen JHJ, Aben KKH, Oldenhof UTH, et al. No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. J Invest Dermatol. 2010; 130: 953-961.
Roelofzen JHJ, van der Valk PGM, Godschalk R, et al. DNA adducts in skin biopsies and 1-hydroxypyrene in urine of psoriasis patients and healthy volunteers following treatment with coal tar. Toxicol Lett 2012; 213: 39-44.
Donaldson M, Chamlin SL, Vivar KL. Pine tar callus: A mimicker of a melanocytic lesion. Pediatr Dermatol 2019; 36: 379-380.
Torfs E, Brackman G. A perspective on the safety of parabens as preservatives in wound care products. Int Wound J 2021; 18: 221-232.
Zeichner JA. Use of topical coal tar foam for the treatment of psoriasis in difficult-to-treat areas. J Clin Aesthet Dermatol 2010; 3: 37-40.
Asz-Sigall D, Tosti A. Scalp psoriasis. In: Tosti A, Asz-Sigall D, Pirmez R, editores. Hair And Scalp Treatments: A Practical Guide. Cham: Springer International Publishing; 2020 [citado 16 de marzo de 2021]. p. 177-95. Disponible en: https://doi.org/10.1007/978-3-030-21555-2_13
Frankel AJ, Zeichner JA, Del Rosso JQ. Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis. J Clin Aesthet Dermatol 2010; 3: 42-45.
Levin EC, Gupta R, Shinkai K. Duration of remission of topical psoriasis therapies. Psoriasis. Forum 2013; 19a: 22-33.
Kortuem KR, Davis MDP, Witman PM, et al. Results of Goeckerman treatment for psoriasis in children: a 21-year retrospective review. Pediatr Dermatol 2010; 27: 518-524.
de Miguel R, el-Azhary R. Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis. Int J Dermatol 2009; 48: 653-658.
Kamaria M, Liao W, Koo JY. How long does the benefit of biologics last? An update on time to relapse and potential for rebound of biologic agents for psoriasis. J Psoriasis Psoriatic Arthritis 2018; 3: 65-70.
Syed YY. Ixekizumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol 2017; 18: 147-158.
Secukinumab withdrawal leads to loss of treatment responses in a majority of subjects with plaque psoriasis with retreatment resulting in rapid regain of responses: a pooled analysis of two phase 3 trials. J Am Acad Dermatol 2016; 74: AB273.
Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous Risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol 2020; 156: 649-658.
Rivera R, Martorell A, López A, et al. Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study. J Eur Acad Dermatol Venereol 2021; 35: e65-e67.
Masson Regnault M, Konstantinou M-P, Khemis A, et al. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. J Eur Acad Dermatol Venereol 2017; 31: 1491-1496.
Fitzmaurice S, Bhutani T, Koo J. Goeckerman regimen for management of psoriasis refractory to biologic therapy: The University of California san Francisco experience. J Am Acad Dermatol 2013; 69: 648-649.
Myers B, Reddy V, Brownstone N, et al. The use of Goeckerman therapy in managing erythrodermic psoriasis resistant to multiple medications. Dermatol Online J 2021; 27: 9.
Wu JJ, Feldman SR, Rastogi S, et al. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatol Treat 2018; 29: 769-774.
Svendsen MT, Feldman SR, Tiedemann SN, et al. Psoriasis patient preferences for topical drugs: A systematic review. J Dermatol Treat 2021; 32: 478-483.
Bhatia A, Singh B, Amarji B, et al. Novel stain-free lecithinized coal tar formulation for psoriasis. Int J Dermatol 2011; 50: 1246-1248.
Sharma M, Sharma G, Singh B, et al. Holistic development of coal tar lotion by embedding design of experiments (DoE) technique: Preclinical investigations. Expert Opin Drug Deliv 2020; 17: 255-273.